Are Vectura Group PLC And Circassia Pharmaceuticals PLC Better Buys Than GlaxoSmithKline plc?

Should you add Vectura Group PLC (LON: VEC) and Circassia Pharmaceuticals PLC (LON: CIR) to your portfolio before GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Although GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has struggled to grow its net profit in recent years, that situation is set to change. Certainly, the pharmaceutical company is continuing to feel the pain of generic competition but, with considerable cost savings to come through over the next couple of years, its margins should pick up moving forward.

In fact, GlaxoSmithKline is set to overturn four years of a falling bottom line to post earnings growth of 11% in financial year 2016. That would be an impressive rate of growth, being around 50% higher than the growth rate of the wider index. And, with GlaxoSmithKline having a price to earnings (P/E) ratio of 16.9, it still offers good value for money for a highly diversified, financially sound pharmaceutical company. In fact, GlaxoSmithKline has a price to earnings growth (PEG) ratio of just 1.4, which indicates that its shares could move much higher over the medium to long term.

Of course, GlaxoSmithKline is one of many impressive pharmaceutical companies listed in the UK. For example, Vectura (LSE: VEC), the biotech respiratory specialist, is also expected to post much-improved financials over the next couple of years, with it set to turn from loss into profit in the current year. In fact, after racking up £48m in pretax losses in the last five years, Vectura is forecast to generate a pretax profit of £2.5m in the current year. And, looking ahead, its pretax profit is set to rise to £20m next year, which is gradually being priced in by the market.

Should you invest £1,000 in Cineworld right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Cineworld made the list?

See the 6 stocks

As such, Vectura’s share price has risen by 38% already this year and, despite trading on a forward P/E ratio of 27.6, it still holds considerable appeal owing to a PEG ratio of just 0.2. Therefore, its share price growth could challenge that of GlaxoSmithKline moving forward.

Meanwhile, Circassia (LSE: CIR) is another pharmaceutical company with considerable potential. Its recent share placing was successful and allowed it to make two key acquisitions, with asthma specialist, Aerocrine, and chronic obstructive pulmonary disease stocks, Prosonix, being acquired for around £240m in cash. And, while the market has been rather subdued regarding the company’s progress (Circassia’s shares are up just 7.5% in the last year), Neil Woodford’s 13.5% stake is likely to help investor sentiment to improve moving forward.

Despite this, GlaxoSmithKline appears to be a better buy than both Circassia and Vectura. That’s at least partly because of its stronger financial standing, black bottom line (Circassia is set to remain a loss-making company over the next two years) and the fact that there is a clear catalyst to push GlaxoSmithKline’s share price higher, in terms of its appealing PEG ratio. In addition, GlaxoSmithKline has greater diversity than its two smaller sector peers and, while investor sentiment has been rather weak in recent years, a refreshed strategy and improving financial performance could enable its share to rise rapidly over the medium to long term.

So, while Circassia and, in particular, Vectura, are worth buying at the present time, GlaxoSmithKline appears to be the preferred option.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Tŵr Mawr lighthouse (meaning "great tower" in Welsh), on Ynys Llanddwyn on Anglesey, Wales, marks the western entrance to the Menai Strait.
Investing Articles

Is the Diageo share price about to go gangbusters?

Harvey Jones thought he spotted the Diageo share price going cheap but jumped too soon. Could his bargain buy finally…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

The Ocado share price is up 48% in a month! Is this the start of a stellar recovery?

Harvey Jones says the Ocado share price is the ultimate binary play. The FTSE 250 stock could fly, or it…

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

Growth, buybacks and dividends galore – are NatWest shares the ultimate no-brainer buy?

NatWest shares are flying again, as we saw in its expectation-thrashing results. Harvey Jones looks at whether the FTSE 100…

Read more »

Female Tesco employee holding produce crate
Investing Articles

Is a UK stock market correction coming?

Our writer’s increasingly concerned about the apparent disconnect between the performance of the UK stock market and that of the…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

The Rolls-Royce share price has soared 66% already this year! Can it really keep going?

Even after a stunning few years, the Rolls-Royce share price has soared by two-thirds already this year. Our writer revisits…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Spare £5k? Here’s how long it would take to generate a second income of £5k every year!

Christopher Ruane explains the maths behind building a second income from dividend shares, as well as some of the opportunities…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

As the FTSE 100 hits an all-time high, is it too late to get in on the boom?

The FTSE 100 index of leading British shares hit a new all-time high in the past week. Our writer explains…

Read more »

Close-up of British bank notes
Investing Articles

3 shares to consider for long-term passive income

Christopher Ruane thinks investors on the hunt for passive income streams should consider this diverse trio of dividend-paying shares.

Read more »